3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
6
avelumab
6
Nivolumab
5
Specimen Handling
4
Magnetic Resonance Spectroscopy
3
Biopsy
3
prednylidene
2
lutetium Lu 177 dotatate
2
deltacortene
2
Prednisone
2
Ipilimumab
2
CTLA-4 Antigen
2
talimogene laherparepvec
1
lenvatinib
1
fludarabine phosphate
1
fludarabine
1
decitabine and cedazuridine drug combination
1
cemiplimab
1
aldesleukin
1
Tacrolimus
1
Sirolimus
1
Saline Solution
1
Radiotherapy
1
Radiosurgery
1
MAPRE1 protein, human
1
Lutetium-177
1
Laparoscopy
1
Exercise Test
1
Cyclophosphamide
1
Axitinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
MAPRE1 protein, human
×
90 days
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled